as described previously (62).

2.4. Western blotting

Animals were decapitated on Day 7 after the injection of Aβ peptides. The hippocampi were removed on ice-cold glass plate and stored at -80°C. The hippocampal tissues were homogenized as described previously (3). Briefly, the hippocampal tissues were homogenized in ice-cold extraction buffer (150 µl of 20 mM Tris-HCl buffer (pH 7.6) containing 150 mM NaCl, 2 mM EDTA · 2Na, 50 mM sodium fluoride, 1 mM sodium vanadate, 1 % NP-40, 1 % sodium deoxycholate, 0.1 % sodium dodecyl sulphate (SDS), 1 mg/ml pepstatin, 1 mg/ml aprotinin, and 1 mg/ml leupeptin). Equal amounts of protein, 20µg/lane, were resolved by a 10 % SDS-polyacrylamide gel electrophoresis, and then transferred electrophoretically to a polyvinylidene difluoride membrane (Millipore Corporation, Billerica, MA). Membranes were incubated in 3 % skim milk in a washing buffer (Tris-buffered saline containing 0.05 % (v/v) Tween-20) for 2 h at room temperature. Then the membranes were incubated at 4°C overnight with a diluted (1:1000) anti-nitrotyrosine mouse clone1A6 (Upstate cell signaling, Lake Placid, USA) or with goat anti-actin primary antibody (1:100) (Santa Cruz Biotechnology Inc., Santa Crutz, CA). After a wash, membranes were incubated with horseradish peroxidase-labeled anti-mouse IgG (1:2000) (Kirkegaard & Perry Laboratories, Baltimore, MD) or with donkey anti-goat IgG secondary antibody (1:2000) (Santa Cruz Biotechnology Inc., Santa Crutz, CA). Immunoreactive complexes on the membrane were

8

detected using Western blotting detection reagents (Amersham Biosciences Inc., Piscataway,

NJ) according to the manufacturer's instructions, and exposed to X-ray film. The intensity of

each protein band on the film, analyzed with the Atto Densitograph 4.1 system (Atto, Tokyo,

Japan), and was corrected with the corresponding β-actin level. The results were expressed as

the percentage of that of the control.

2.5. Novel object recognition task

This task, based on the spontaneous tendency of rodents to explore a novel object more

often than a familiar one (16), was performed during Day 8 - Day 10 after the $i.c.v.$ injection

of Aβ peptides as described previously (3). A plastic chamber (35× 35× 35 cm) was used in

low light condition during the light phase of the light/dark cycle. The general procedure

consisted of three different phases: a habituation phase, an acquisition phase, and a retention

phase. On the 1st day (habituation phase), mice were individually subjected to a single

familiarization session of 10 min, during which they were introduced in the empty arena, in

order to become familiar with the apparatus. On the 2nd day (acquisition phase) animals were

subjected to a single 10-min session, during which floor-fixed two objects (A and B) were

placed in a symmetric position from the centre of the arena, 15 cm from each and 8 cm from

the nearest wall. The two objects, made of the same wooden material with the similar color

and smell, were different in shape but identical in size. Mice were allowed to explore the

objects in the open field. A preference index for each mouse was expressed as a ratio of the

9

amount of time spent exploring object A (TA ×100)/ (TA + TB), where TA and TB are the

time spent on exploring object A and object B, respectively. On the 3rd day (retention phase),

mice were allowed to explore the open field in the presence of two objects: the familiar object

A and a novel object C in different shape but in similar color and size (A and C). A

recognition index, calculated for each mouse, was expressed as the ratio (TC ×100)/ (TA +

TC), where TA and TC are the time spent during retention phase on object A and object C,

respectively. The time spent exploring the object (nose pointing toward the object at a

distance ≤ 1 cm) was recorded by hand.

2.6. Statistical analyses

The results are expressed as the mean ± S.E.. Statistical significance was determined with

one-way ANOVA followed by the Bonferroni multiple comparisons test. $p < 0.05$ was taken as

a significant level of difference.

3. Results

3.1. TNF-α was involved in $A\beta_{25-35}$-induced impairment of recognition memory

The expression of TNF-α and iNOS mRNA in the hippocampus of mice was investigated at

different time points after the i.c.v.-injection of $A\beta_{25-35}$. At two-hour time point, $A\beta_{25-35}$

increased the mRNA expressions of TNF-α and iNOS, the expression of the former was

stronger than that of the latter (Fig. 2 A). $A\beta_{25-35}$ did not increase the expression of iNOS

mRNA in TNF-α (-/-) mouse at the two-hour time point (Fig.2 B). The selective inhibition of

10

iNOS activity by aminoguanidine (14) or TNF-α (-/-) prevented Aβ_{25-35} induced nitration of

proteins in the hippocampus or the impairment of recognition memory in mice (Fig.2 C, D).

The Western blott analysis of protein nitration revealed only a single band for nitrated proteins

at the size of 70 kDa. Through extensive studies with different anti-nitrotyrosine antibodies

from different origin, we found that the detection of this single band is owing to the selectivity

of the anti-nitrotyrosine mouse antibody (3). These results, together with previous reports

(2,13,36,65), confirmed that TNF-α is essential for the neurotoxicity of Aβ.

3.2. Restraining TNF-α by thalidomide prevented Aβ-induced impairment of recognition memory

The consistent involvement of TNF-α in the neurotoxicity of Aβ prompted us to examine

an available candidate for anti-TNF-α remedy. Thalidomide, an immunomodulatory drug, has

recently been suggested for the treatment of neurodegenerative disease as a selective inhibitor

of TNF-α (21,60). Thalidomide inhibits the synthesis of TNF-α through the degradation of

mRNA (37). We reexamined the selectivity of thalidomide-induced degradation of TNF-α

mRNA. Thalidomide suppressed the increase of both TNF-α and iNOS mRNA induced by

Aβ_{1-40} (Fig. 3 A,B). The decrease of iNOS mRNA might be due to the decrease of TNF-α

(32). The mRNA expressions of brain-derived neurotrophic factor (BDNF) and glial cell-

derived neurotrophic factor (GDNF), however, were not affected either by Aβ_{1-40} injection or

thalidomide treatment (Fig. 3 C, D). Either the daily treatment with thalidomide or the *i.c.v.*-

11

injection of an anti-TNF-α antibody prevented the nitration of proteins in the hippocampus and the impairment of recognition memory induced by Aβ_{25-35} or Aβ_{1-40} (Fig. 4 A, B). The preventive effects of the anti-TNF-α antibody was consistent with previous reports (36,65), and supported the validity of targeting TNF-α by thalidomide to prevent the neurotoxicity of Aβ.

4. Discussion

Providing effective medication or practical strategy for the treatment of the cognitive deficits in AD can have a dramatic effect on the quality of life of a patient.

As a strategy to prevent the cognitive decline in AD, anti-oxidants are well recommended based on the association of the increased cerebral oxidative damage with the progress of the disease (7,22,45). The oxidative damage in the brain of AD is mostly ascribed to the increased level of Aβ that induces the peroxynitrite-mediated nitration of proteins and the resultant irreversible loss of function (9,10,46,53,54,67). It is therefore thus suggested that preventing the formation of peroxynitrite should be the early strategy for interrupting the cognitive failure in AD. Peroxynitrite is the product of the inter-action of nitric oxide (NO) and superoxide (6,46). Although the half-life of NO is extremely short, peroxynitrite could be formed at a rate more than three times faster than the scavenging of superoxide by superoxide dismutase, implying criticality of the over-produced NO (5). The overproduction of NO by Aβ is ascribed to the overexpression of iNOS (1,23,25,40,47,59,64). The deletion of iNOS

12

or inhibition of the activity prevents peroxynitrite-mediated damage or the impairment of memory induced by $A\beta_{1-40}$ (25,40,58). Observation of iNOS overexpression in the brain of AD (33,61), supports an anti-iNOS strategy (40,59). However, the involvement of iNOS in the important physiology of life such as sexuality and sleep in the recent reports makes the strategy less favorable (20,26). Therefore, restraining the overproduction of iNOS without affecting its normal expression and function is desired. The involvement of the TNF-α in iNOS-mediated neurotoxicity of $A\beta_{1-40}$ (2,13,36,65), points out a better strategy of targeting TNF-α to prevent the iNOS-driven-peroxynitrite-mediated impairment of memory in the neurotoxicity of $A\beta$.

In the present study, we examined the feasibility of a strategy of targeting TNF-α for the prevention of $A\beta$-induced impairment of memory. To confirm the involvement of TNF-α in the $A\beta$-induced impairment of recognition memory, $A\beta_{25-35}$, the most toxic $A\beta$ species detected in AD brain, and TNF-α (-/-) mouse were utilized. $A\beta_{25-35}$ did not induce the impairment of recognition memory in TNF-α (-/-) mouse. The serious involvement of TNF-α was consistent with the previous reports (2,13,36,65), and boosted the prospect of an anti-TNF-α strategy to prevent the neurotoxicity of $A\beta$. Considering the current availability for practice, thalidomide was selected due to its preferential degradative effect on the mRNA of TNF-α (32,37). Thalidomide preferentially suppressed the increase of TNF-α mRNA and prevented the $A\beta$-induced impairment of recognition memory. An anti-TNF-α antibody also

13

provide prevention against the impairment of recognition memory induced by Aβ, validating

the usefulness of the strategy of targeting TNF-α.

A variety of inhibitory agents of the synthesis or the activity of TNF-α is widely

investigated and currently used as remedy in practice (4,35). However, the penetrating ability

of the blood-brain-barrier (BBB) of these agents is one of the factors to challenge their

application for the ailments in the central nervous system. With the ability of penetrating of

BBB, thalidomide is recently emerged as good candidate for the treatment for

neurodegenerative diseases due to its potent inhibitory property for the synthesis of TNF-α

(21,24,60). The drug has recently been reintroduced for treating leprosy, although once was

withdrawn from the general market because of its catastrophic adverse effect of teratogenesis

(31). The treatment with thalidomide in AD may have very limited chance, in the elderly, of

causing teratogenesis in the progeny. Since thalidomide has a neglectable weak inhibitory

effect for NOS including iNOS (52), the attenuation of iNOS-related pathology could most

likely be contributed by its inhibition of the synthesis of TNF-α (32). These reports qualify

thalidomide as an ideal agent for reducing the iNOS/peroxynitrite related pathology via

restraining the increase of TNF-α without evidently harm the physiological function of iNOS.

The neuroprotective effects of thalidomide in an animal model of inflamed brain pathology of

AD in a recent study also recommend and support the use of the drug (48).

In conclusion, the usefulness of restraining TNF-α by thalidomide to prevent Aβ-induced

14

impairment of memory in mice would provide a practical fresh strategy for the management

of cognitive deficits in AD.

15

16

References:

[1] Akama KT, Albanese C, Pestell RG, Van Eldik LJ. Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc Natl Acad Sci USA, 1998; 95:5795-5800.

[2] Akama KT, Van Eldik LJ. β-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNF-α)-dependent, and involves a TNF-α receptor-associated factor- and NF kappa B-inducing kinase-dependent signaling mechanism. J Biol Chem 2000; 275:7918-7924.

[3] Alkam T, Nitta A, Mizoguchi H, Itoh A, Nabeshima T. A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Abeta (25-35). Behav Brain Res, 2007; 180:139-145.

[4] Baugh JA, Bucala R. Mechanisms for modulating TNF alpha in immune and inflammatory disease. Curr Opin Drug Discov Devel, 2001; 4:635-650.

[5] Beckman JS. Peroxynitrite versus hydroxyl radical: the role of nitric oxide in superoxide-dependent cerebral injury. Ann N Y Acad Sci, 1994; 738:69-75.

[6] Beckman JS, Crow JP. Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem Soc Trans, 1993; 21:330-334.

[7] Behl C, Moosmann B. Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Radic Biol Med, 2002; 33:182-191.

17

[8] Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhoj P, Pedersen BK. A high plasma concentration of TNF-α is associated with dementia in centenarians, J Gerontol A Biol Sci Med Sci, 1999; 54:357-364.

[9] Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med, 2001; 7:548-554.

[10] Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 2003; 85:1394-1401.

[11] Chan ED, Riches DW. Potential role of the JNK/SAPK signal transduction pathway in the induction of iNOS by TNF-alpha. Biochem Biophys Res Commun, 1998; 253:790-796.

[12] Chung F, Lu J, Palmer BD, Kestell P, Browett P, Baguley BC, Tingle M, Ching LM. Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin Cancer Res, 2004; 10:5949-5956.

[13] Combs CK, Karlo JC, Kao SC, Landreth GE. β-Amyloid stimulation of microglia and monocytes results in TNF-α dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 2001; 21:1179-1188.

[14] Corbett JA, McDaniel ML. Selective inhibition of inducible nitric oxide synthase by

18

aminoguanidine. Methods Enzymol, 1996; 268:398-408.

|15| Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci, 2002; 5:452-457.

|16| Ennaceur A and Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res 1998; 31:47-59

|17| Fillit H, Ding WH, Buee L, Kalman J, Altstiel L, Lawlor B, Wolf-Klein G (1991) Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett, 129:318-320

|18| Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120:885-890.

|19| Golde TE, Alzheimer disease therapy: can the Amyloid cascade be halted? J Clin Invest, 2003; 111:11-8

|20| Gonzalez-Cadavid NF, Rajfer J. The pleiotropic effects of inducible nitric oxide synthase (iNOS) on the physiology and pathology of penile erection. Curr Pharm Des, 2005; 11:4041-4046.

|21| Greig NH, Giordano T, Zhu X, Yu QS, Perry TA, Holloway HW, Brossi A, Rogers

19

JT, Sambamurti K, Lahiri DK. Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. Acta Neurobiol Exp, 2004; 64:1-9.

|22| Grundman M, Grundman M, Delancy P. Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc, 2002; 61:191-202.

|23| Hu J, Akama KT, Krafft GA, Chromy BA, Van Eldik LJ. Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res, 1998; 785:195-206.

|24| Huang YJ, Liao JF, Tsai TH. Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography. Biomed Chromatogr, 2005; 19:488-493.

|25| Ishii K, Muelhauser F, Liebl U, Picard M, Kühl S, Penke B, Bayer T, Wiessler M, Hennerici M, Beyreuther K, Hartmann T, Fassbender K. Subacute NO generation induced by Alzheimer's beta-amyloid in the living brain: reversal by inhibition of the inducible NO synthase. FASEB J, 2000; 14:1485-1489.

|26| Kalinchuk AV, Stenberg D, Rosenberg PA, Porkka-Heiskanen T. Inducible and neuronal nitric oxide synthases (NOS) have complementary roles in recovery sleep induction. Eur J Neurosci, 2006; 24:1443-1456.

|27| Keller JN. Oxidative damage and oxidative stress in Alzheimer's disease. Res Pract Alzheimer's Dis, 2006; 11:110-114

20

|28| Koppal T, Drake J, Yatin S, Jordan B, Varadarajan S, Bettenhausen L, Butterfield DA. Peroxynitrite-induced alterations in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's disease. J Neurochem, 1999; 72:310-317.

|29| Kubo T, Nishimura S, Kumagae Y, Kaneko I. In vivo conversion of racemized beta-amyloid (|D-Ser 26|A beta 1-40) to truncated and toxic fragments (|D-Ser 26|A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res, 2002; 70:474-483.

|30| Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets, 2003; 4: 97-112.

|31| Lash JW, Saxén L. Human Teratogenesis: invitro studies on thalidomide-inhibited chondrogenesis. Dev Biol, 1972; 28:61-70.

|32| Lopez-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology, 1996; 23:1616-1621.

|33| Luth HJ, Munch G, Arendt T. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res, 2002; 953:135-143.

|34| Maurice T, Lockart BP, Privat A. Amnesia induced by centrally administered β-

amyloid peptides involves cholinergic dysfunction. Brain Res, 1996; 706:181-193.

|35| McDermott MF. TNF and TNFR biology in health and disease. Cell Mol Biol, 2001; 47:619-635.

|36| Medeiros R, Prediger RD, Passos GF, Pandolfo P, Duarte FS, Franco JL, Dafre AL, Di Giunta G, Figueiredo CP, Takahashi RN, Campos MM, Calixto JB. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci, 2007; 27:5394-5404.

|37| Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med, 1993; 177:1675-1680.

|38| Mouri A, Noda Y, Hara H, Mizoguchi H, Tabira T, Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J, 2007; 21:2135-2148.

|39| Nabeshima T, Nitta A. Memory impairment and neuronal dysfunction induced by β-amyloid protein in rats. Tohoku J Exp Med, 1994; 174:241-249.

|40| Nathan C, Calingasan N, Nezezon J, Ding A, Lucia MS, La Perle K, Fuortes M, Lin M, Ehrt S, Kwon NS, Chen J, Vodovotz Y, Kipiani K, Beal MF. Protection from

Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med, 2005; 202:1163-1169.

|41| Nitta A, Itoh A, Hasegawa T, Nabeshima T. β-Amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett, 1994; 170:63-66.

|42| Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. Arch Neurol, 1997; 54:1234-1240.

|43| Perry RT, Collins JS, Wiener H, Acton R, Go RC. The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging, 2001; 22:873-883.

|44| Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of Abeta peptides: contributions of the β25-35 region to aggregation and neurotoxicity. J Neurochem, 1995; 64: 253-265.

|45| Praticò D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Arch Neurol, 2002; 59:972-976.

|46| Reiter CD, Teng RJ, Beckman JS. Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J Biol Chem, 2000; 275:32460-32466.

|47| Rodrigo J, Fernández-Vizarra P, Castro-Blanco S, Bentura ML, Nieto M, Gómez-Isla T, Martínez-Murillo R, Martínez A, Serrano J, Fernández AP. Nitric oxide in the cerebral

23

cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice. Neuroscience, 2004; 128:73-89.

|48| Ryu JK, McLarnon JG. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain. Neurobiol Dis, 2007; |Epub ahead of print|.

|49| Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991; 6:487-98.

|50| Selkoe DJ. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest, 2002; 110:1375-1381.

|51| Shalit F, Sredni B, Rosenblatt-Bin H, Kazimirsky G, Brodie C, Huberman M. Beta-amyloid peptide induces tumor necrosis factor-alpha and nitric oxide production in murine macrophage cultures. Neuroreport, 1997; 8:3577-3580.

|52| Shimazawa R, Sano H, Tanatani A, Miyachi H, Hashimoto Y. Thalidomide as a nitric oxide synthase inhibitor and its structural development. Chem Pharm Bull, 2004; 52:498-499.

|53| Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N. Oxidative damage in Alzheimer's. Nature, 1996; 382: 120-1

|54| Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci, 1997; 17:2653-2657.

|55| Taniguchi T, Tanaka M, Ikeda A, Momotani E, Sekikawa K. Failure of germinal center

formation and impairment of response to endotoxin in tumor necrosis factor-alpha

deficient mice. Lab Invest, 1997; 77:647-658.

[56] Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation

precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry, 2003;

74:1200-1205.

[57] Tohgi H, Abe T, Yamazaki K., Murata T, Ishizaki E, Isobe C. Alterations of 3

nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with

Alzheimer's disease. Neurosci Lett, 1999; 269:52-54.

[58] Tran MH, Yamada K, Nakajima A, Mizuno M, He J, Kamei H, Nabeshima T. Tyrosine

nitration of a synaptic protein synaptophysin contributes to amyloid β-peptide-induced

cholinergic dysfunction. Mol Psychiatry 2003; 8: 407-412.

[59] Tran MH, Yamada K, Olariu A, Mizuno M, Ren XH, Nabeshima T. Amyloid beta-

peptide induces nitric oxide production in rat hippocampus: association with

cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors.

FASEB J, 2001; 15:1407-1409.

[60] Tweedie D, Sambamurti K, Greig NH. TNF-alpha inhibition as a treatment strategy for

neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res,

2007; 4:378-385.

[61] Vodovotz Y, Lucia MS, Flanders KC, Chesler L, Xie QW, Smith TW, Weidner J,

25

Mumford R, Webber R, Nathan C, Roberts AB, Lippa CF, Sporn MB. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med, 1996; 184:1425-1433.

|62| Wada R, Tifft CJ, Proia RL. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci USA, 2000; 97:10954-10959.

|63| Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron, 2004; 44:181-193.

|64| Wang Q, Rowan MJ, Anwyl R. ß-Amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci, 2004; 24:6049-6056.

|65| Wang Q, Wu J, Rowan MJ, Anwyl R. α-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci, 2005; 22:2827-2832.

|66| Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med, 2006; 12:1005-1015.

|67| Xie Z, Wei M, Morgan TE, Fabrizio P, Han D, Finch CE, Longo VD. Peroxynitrite mediates neurotoxicity of amyloid beta-peptide1-42 and lipopolysaccharide-activated microglia. J Neurosci, 2002; 22:3484-3492.

26

[68] Zameer A, Schulz P, Wang MS, Sierks MR. Single chain Fv antibodies against the 25-35 Aβ fragments inhibit aggregation and toxicity of Aβ42. Biochemistry, 2006; 45:11532-11539.

[69] Zeng C, Lee JT, Chen H, Chen S, Hsu CY, Xu J. Amyloid-β peptide enhances tumor necrosis factor-alpha-induced iNOS through neutral sphingomyelinase/ceramide pathway in oligodendrocytes. J Neurochem, 2005; 94:703-712.